GLND has declined approximately -32% over the past 30 days amid high volatility following its recent listing on NASDAQ. Over the past quarter, the stock is down around -26%, reflecting post-listing hype fade and broader energy sector pressures.

Crescent Biopharma (CBIO) stock surged +75% over the last 30 days, driven by fresh analyst buy ratings and sustained momentum from clinical trial advancements. Over the past quarter, shares climbed +44%, fueled by the first patient dosing in the ASCEND trial and positive full-year earnings outlook highlighting cash runway into 2028.

VET declined approximately -12% over the past 30 days amid a broader energy sector pullback and softening oil prices following early April peaks. Over the past quarter, VET rose +28%, driven by strong Q1 2026 production beats, strategic asset acquisitions in Germany, and favorable European natural gas pricing.

Venture Global (VG) stock declined 23% over the last 30 days, driven by profit-taking after a March rally, analyst price target reductions, and technical sell signals. The stock rose 30% over the past quarter, fueled by surging LNG demand, new long-term contracts, and strong Q4 earnings.

IPI declined approximately 12% over the past 30 days, pulling back from mid-March highs amid profit-taking and softer commodity sentiment. Over the past quarter, the stock rose about 4%, buoyed by a strong Q4 earnings report and rising fertilizer demand.

CG Oncology's shares have shown strong upward momentum in recent weeks, driven by clinical progress and analyst enthusiasm. Topline data from the pivotal Phase 3 PIVOT-006 trial is slated for the first half of 2026, a key catalyst for potential approval.

Relay Therapeutics (RLAY) stock surged +62% over the past 30 days, driven by positive clinical data reveals on zovegalisib, including expansions into vascular anomalies and combination therapy updates. The stock climbed +112% over the past quarter, fueled by FDA Breakthrough Therapy designation for zovegalisib in breast cancer and narrowing losses in Q4 earnings.

Sustained higher interest rates could enhance net interest margins (NIM, a key profitability measure for banks) for major holdings, positioning FNCL for potential outperformance. Growth in capital markets activity and merger-and-acquisition (M&A) deals may boost investment banking revenues within the ETF's diversified financial exposures.

IYF rose +8.2% over the past 30 days, driven by a rebound in major bank stocks and diversified financial holdings. Over the past quarter, the ETF gained +0.8%, remaining relatively flat amid broader market volatility.

Shares of DOW are plunging approximately 12% in Friday's session, declining from a prior close of $39.92 to around $35.13, as the Iran conflict-driven petrochemical pricing advantage that powered the stock's 70%+ year-to-date rally rapidly unravels. The primary catalyst is the accelerating unwind of the geopolitical war premium: advancing U.S.-Iran diplomatic talks threaten to reopen the Strait of Hormuz, which would collapse the artificially elevated U.S.-to-Asia petrochemical pricing arbitrage that has been a direct earnings tailwind for Dow Inc.

BA stock rose +6% over the past 30 days, rebounding from March lows amid positive Q1 delivery numbers and improved market sentiment. Over the past quarter, shares declined -9%, reflecting ongoing production challenges and supply chain issues despite strong backlog demand.

Shares of VG are plunging approximately 12% in Friday's session, declining from a prior close of $12.68 to the vicinity of $11.16, as the geopolitical premium that drove the LNG stock's dramatic year-to-date rally rapidly unravels. The primary catalyst is the accelerating retreat in global LNG and crude oil prices as U.S.-Iran diplomatic engagement advances, stripping the conflict-driven risk premium that had boosted Venture Global nearly 90% year-to-date.

Shares of COP are declining approximately 6% in Friday's session, extending a sustained retreat from the stock's 52-week high of $135.87 reached on March 30, 2026, as WTI crude prices continue to erode toward the high-$80s. The primary catalyst is the accelerating unwind of the geopolitical "war premium" built into oil prices during the U.S.-Iran conflict, with WTI crude having shed more than $25 per barrel from its early-April peak above $117.

Shares of XOM are declining approximately 5% in Friday's session, with the stock sliding from a prior close of $151.98 toward the $144 range as crude oil prices continue their prolonged retreat from April highs. The primary catalyst is a sustained collapse in WTI crude oil prices, which have fallen from a peak above $114 per barrel to the low-$90s as geopolitical risk premiums tied to the U.S.-Iran conflict steadily erode.

Shares of NFLX are falling approximately 10.55% in Friday's premarket session, sliding from a prior close of $107.79 to around $96.42, following the company's Q1 2026 earnings release after Thursday's market close. Q1 results comprehensively beat expectations — revenue of $12.25 billion topped estimates of $12.18 billion, and EPS of $1.23 trounced the consensus forecast of $0.79 by 55.7%.

Shares of BMI are tumbling approximately 18% in Friday's premarket session following a deeply disappointing Q1 2026 earnings report released before market open. Revenue came in at $202.3 million, a 9% year-over-year decline and a significant miss against analyst consensus expectations of roughly $230–$232 million.

Netflix reported Q1 2026 revenue of $12.25 billion, topping consensus estimates of $12.18 billion and up 16% year-over-year. Diluted earnings per share (EPS) came in at $1.23, nearly double the $0.76-$0.79 expected by analysts.

TSMC reported Q1 2026 revenue of $35.90 billion, a 35.1% increase year-over-year (YoY) and 6.4% quarter-over-quarter (QoQ), surpassing consensus estimates around $35.5 billion. Diluted earnings per share (EPS) reached NT$22.08 ($3.49 per American Depositary Receipt or ADR), up 58.3% YoY, beating analyst expectations of NT$20.88.

Charles Schwab reported record net revenues of $6.5 billion for Q1 2026, up 16% year-over-year. GAAP diluted EPS rose 38% to $1.37, beating consensus estimates around $1.39 on an adjusted basis of $1.43.

Abbott reported first-quarter sales of $11.16 billion, up 7.8% on a reported basis and beating consensus estimates of approximately $11.01 billion. Adjusted diluted earnings per share (EPS) came in at $1.15, meeting analyst expectations and rising 6% year-over-year (YoY).